The treatment of HPV-positive tumor cells with an HDAC inhibitor increases the surface expression of the major histocompatibility complex class I (MHC-I) molecules, increasing the susceptibility of tumor cells to E7-specific CD8+ T cells (Lee et al., 2013). This evidence concerns the gene HDAC9 and neoplasm.